Please login to the form below

Not currently logged in
Email:
Password:

MedImmune

This page shows the latest MedImmune news and features for those working in and with pharma, biotech and healthcare.

Regeneron and Teva close gap on rivals with NGF pain drug

Regeneron and Teva close gap on rivals with NGF pain drug

NGF inhibitors have had a chequered history, with a long list of discontinued candidates, mainly due to side effect issues, from the likes of AstraZeneca/Medimmune and AbbVie, amongst others.  Amgen

Latest news

More from news
Approximately 12 fully matching, plus 82 partially matching documents found.

Latest Intelligence

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    This physical environment gives us an opportunity to work in a different way,” said Jane Osbourn, the company’s site lead and vice-president for research and development at MedImmune, its

  • Deal Watch March 2017 Deal Watch March 2017

    Sanofi, MedImmune, AstraZeneca, Astellas, Novartis and more feature in this month's pharma deals round-up. ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development. MEDI8897; monoclonal antibody to respiratory syncytial virus in phase

  • Deal Watch October 2016 Deal Watch October 2016

    Licensee / Acquirer. Deal type. Product /technology. Headline $m. Medimmune / AstraZeneca (UK).

  • Deal Watch February 2016 Deal Watch February 2016

    We have seen this for several of the large pharma firms and this month AstraZeneca licensed an antibody developed by MedImmune to start-up company Corvidia Therapeutics concurrently with Corvidia's ... acquisition - corporate. 29.35. AstraZeneca/

  • Pharma deals in August 2015 Pharma deals in August 2015

    MedImmune has paid $27.5m upfront, with a further $700m in milestones and double digit tiered royalties. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for cervical and head &neck cancer.

More from intelligence
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest appointments

  • AZ and Medimmune bolsters immuno-oncology leadership AZ and Medimmune bolsters immuno-oncology leadership

    Dr Jean-Charles Soria and Dr Geoffrey Kim join the company. AstraZeneca and its global biologics research and development arm MedImmune, has appointed Dr Geoffrey Kim and Dr Jean-Charles Soria, ... Soria also taking up a leadership role within AZ’s

  • AstraZeneca appoints head of oncology AstraZeneca appoints head of oncology

    Dr Jamie Freedman joins from AZ subsidiary MedImmune. AstraZeneca has appointed Dr Jamie Freedman as its new head of oncology, succeeding Dr Mondher Mahjoubi. ... Dr Freedman moves to AstraZeneca from its subsidiary MedImmune, where he was senior vice

  • Nanobiotix strengthens US leadership team Nanobiotix strengthens US leadership team

    He has also served as vice president and head of clinical development oncology at MannKind, and held clinical leadership positions at MedImmune and Sigma-Tau Research.

  • Envigo appoints Patricia Henahan as chief financial officer Envigo appoints Patricia Henahan as chief financial officer

    Henahan brings 15 years of financial experience in the life science sector, including senior leadership roles at AstraZeneca, Eli Lilly and MedImmune.

  • Sanofi appoints Dr Yong-Jun Liu as head of research Sanofi appoints Dr Yong-Jun Liu as head of research

    He brings experience from MedImmune and the Baylor Research Institute. Sanofi has appointed Dr Yong-Jun Liu as head of research, global research and development, which he will commence from 1 ... In January 2014, Dr Liu was appointed head of research at

More from appointments
Approximately 5 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics